C4 Therapeutics (CCCC) Total Debt (2020 - 2023)

C4 Therapeutics' Total Debt history runs 4 years deep, the most recent figure standing at $10.3 million for Q2 2023.

• In Q2 2023, Total Debt fell 7.08% year-over-year to $10.3 million; the TTM figure through Jun 2023 stood at $10.3 million (down 7.08% YoY), while the FY2022 annual figure was $11.5 million, up 6.63% from the prior year.
• Total Debt was $10.3 million for Q2 2023 at C4 Therapeutics, down from $10.9 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $11.5 million in Q4 2022 to a low of $9.9 million in Q3 2020.
• Historically, Total Debt has averaged $10.7 million across 4 years, with a median of $10.7 million in 2021.
• The sharpest annual moves came in 2021 and 2023: Total Debt grew 7.2% in 2021, then fell 7.08% in 2023.
• A 4-year view of Total Debt shows it stood at $10.1 million in 2020, then grew by 7.12% to $10.8 million in 2021, then rose by 6.63% to $11.5 million in 2022, then retreated by 9.99% to $10.3 million in 2023.
• The last three Total Debt figures came in at $10.3 million (Q2 2023), $10.9 million (Q1 2023), and $11.5 million (Q4 2022), per Business Quant data.